Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

NCT01909934 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01909934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01909934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Completed
Start date
January 23, 2014
Completion date
August 29, 2024
Enrollment
50 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma